pentobarbital will minimize the level or effect of gefitinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or impact of dapsone by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Mysterious.
Keep an eye on Intently (one)pentobarbital will lower the level or result of levamlodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the extent or effect of fesoterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will lessen the extent or result of levamlodipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the level or result of irinotecan liposomal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
Contraindicated (one)pentobarbital will minimize the extent or effect of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with robust CYP3A4 inducers may result in lessened serum concentrations and lack of antimalarial efficacy
Contraindicated (one)pentobarbital will reduce the level or result of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will reduce the extent or impact of piroxicam by influencing hepatic enzyme CYP2C9/10 metabolism. Minimal/Significance Mysterious.
Therapy must be administered with warning, if whatsoever, to sufferers who are mentally depressed, have get more info suicidal tendencies, or background of drug abuse
pentobarbital will decrease the extent or outcome of tinidazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
By clicking mail, you acknowledge that you have permission to e-mail the recipient with this facts.
Contraindicated (1)pentobarbital will decrease the extent or result of lonafarnib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib can be a sensitive CYP3A4 substrate. Coadministration with strong or average CYP3A4 inducers is contraindicated.
With therapeutic doses of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.